Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial.

@article{Realdi1990RecombinantHI,
  title={Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial.},
  author={Giuseppe Realdi and Giuseppe Diodati and Paola Bonetti and Sergio Scaccabarozzi and Alfredo Alberti and Arturo Ruol},
  journal={Journal of hepatology},
  year={1990},
  volume={11 Suppl 1},
  pages={S68-71}
}
A randomized, controlled trial was undertaken to evaluate the response to recombinant interferon alfa-2a in patients with hepatitis B surface antigen negative chronic active hepatitis of unknown aetiology (community-acquired non-A, non-B hepatitis). Thirty patients were treated with thrice weekly interferon in a dose of 6 million units for 1 month, followed… CONTINUE READING